The role of circulating tumor DNA (ctDNA) in urothelial cancers

Jeanny B. Aragon-Ching

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002317

PDF (563KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002317 DOI: 10.37349/etat.2025.1002317
Commentary
research-article
The role of circulating tumor DNA (ctDNA) in urothelial cancers
Author information +
History +
PDF (563KB)

Abstract

The role of circulating tumor DNA (ctDNA) in urothelial cancers is a rapidly evolving area of research. Urothelial cancer is the most common subtype of bladder cancer, and biomarkers that predict response or prognosticate outcomes have been long sought after. Tumor-informed ctDNA assays have been utilized in several other cancers and increasingly used in both muscle invasive bladder cancer (MIBC) and metastatic urothelial cancer (mUC) to inform treatment decision-making. While a universal consensus on ctDNA testing has not been fully defined and discussed herein, understanding its benefits and limitations is important to help guide the practical application in the clinic.

Keywords

Circulating tumor DNA (ctDNA) / bladder cancer / urothelial cancer / muscle invasive bladder cancer (MIBC) / metastatic urothelial cancer (mUC)

Cite this article

Download citation ▾
Jeanny B. Aragon-Ching. The role of circulating tumor DNA (ctDNA) in urothelial cancers. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002317 DOI:10.37349/etat.2025.1002317

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Wéber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024; 42: 237.

[2]

Jun T, Anker J, Galsky MD. Biomarkers for therapy selection in metastatic urothelial cancer. J Cancer Metastasis Treat. 2022; 8: 1.

[3]

Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11: 426-37.

[4]

Pantel K, Alix-Panabières C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2025; 22: 65-77.

[5]

Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020; 1: 873-81.

[6]

Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020; 1: 276-90.

[7]

Henriksen TV, Demuth C, Frydendahl A, Nors J, Nesic M, Rasmussen MH, et al. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Ann Oncol. 2024; 35: 229-39.

[8]

Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. ; DYNAMIC Investigators. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022; 386: 2261-72.

[9]

Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al.; TRACERx Consortium; Birkbak NJ, McGranahan N, Swanton C. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023; 616: 553-62.

[10]

Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, et al. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer Discov. 2022; 12: 1690-701.

[11]

Barata PC, Zarrabi KK, Bex A, Grivas P, Hermann K, Hofman MS, et al. Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers. Eur Urol. 2025; 87: 412-23.

[12]

Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019; 37: 1547-57.

[13]

Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al. ; IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22: 525-37.

[14]

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021; 595: 432-7.

[15]

Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol. 2024; 85: 114-22.

[16]

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384: 2102-14.

[17]

Sfakianos JP, Basu A, Laliotis G, Cumarasamy S, Rich JM, Kommalapati A, et al. Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. Eur Urol Oncol. 2025; 8: 306-14.

[18]

Ayanambakkam A, Lam AB, Popuri N, Mitta LA, Xu C, Patel S, et al. Longitudinal analysis of circulating tumor DNA in localized and metastatic urothelial cancer. J Clin Oncol. 2024; 42: 4587.

[19]

Bellmunt J, Russell BM, Szabados B, Valderrama BP, Nadal R. Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma. Am Soc Clin Oncol Educ Book. 2025; 45: e471912.

[20]

Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer. 2022; 126: 430-9.

[21]

Belay S, Rice D, Li W, Aragon-Ching JB. Maintenance avelumab in a patient with metastatic urothelial carcinoma on hemodialysis: A case report. Curr Probl Cancer Case Rep. 2022; 8: 100189.

[22]

Tolmeijer SH, van Wilpe S, Geerlings MJ, von Rhein D, Smilde TJ, Kloots ISH, et al. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. Eur Urol Oncol. 2024; 7: 282-91.

[23]

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, et al. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017; 23: 6487-97.

[24]

Zhang J, Dai D, Tian J, Li L, Bai J, Xu Y, et al. Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer. Front Oncol. 2021; 11: 657483.

[25]

Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med. 2021; 27: 793-801.

[26]

Chauhan PS, Shiang A, Alahi I, Sundby RT, Feng W, Gungoren B, et al. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. NPJ Precis Oncol. 2023; 7: 6.

[27]

Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2024; 85: 17-31.

PDF (563KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉